Veterinary Active Pharmaceutical Ingredients Manufacturing

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

The global Veterinary Active Pharmaceutical Ingredients (API) market is estimated to reach USD 12.4 billion by 2035, growing at a CAGR of approximately 6.5% during the forecast period from 2025 to 2035. This growth trajectory is driven by increasing pet ownership, a rising demand for high-quality veterinary care, and the growing prevalence of infectious diseases among livestock and companion animals. Additionally, advancements in veterinary medicine, alongside heightened awareness of animal health, are propelling market expansion. The increasing focus on improving livestock productivity and the welfare of companion animals are contributing factors that are expected to further enhance market growth over the coming years. Regulatory developments in veterinary pharmaceuticals are also expected to positively impact market dynamics, fostering innovation and investment in this crucial sector.

Growth Factor of the Market

Various factors are contributing to the growth of the Veterinary Active Pharmaceutical Ingredients market. One major factor is the increasing prevalence of zoonotic diseases, which has led to heightened awareness and demand for veterinary pharmaceuticals to improve animal health and control disease transmission to humans. Another driver is the growing trend of pet ownership, particularly in developing regions, as more households prioritize the health and well-being of their pets, resulting in greater investment in veterinary care. Additionally, advancements in veterinary medicine, including the development of new APIs and formulations, are driving demand. The rise in livestock production to meet global food demand further fuels the market, as farmers seek effective medications to maintain animal health and productivity. Furthermore, the increasing adoption of preventive health measures, such as vaccinations and regular health assessments, is expected to support market growth.

Key Highlights of the Market

• The Veterinary API market is projected to grow at a CAGR of 6.5% from 2025 to 2035.
• Antibiotics and antiparasitics are the leading product types in the market.
• Companion animals are experiencing an increase in demand for active pharmaceutical ingredients.
• Online pharmacies are becoming a significant distribution channel for veterinary APIs.
• North America is expected to dominate the market due to advanced veterinary care systems.

By Product Type

Antibiotics:

Antibiotics represent a major segment within the Veterinary Active Pharmaceutical Ingredients market. These are crucial for managing bacterial infections in both livestock and companion animals. The increasing incidence of antibiotic-resistant bacteria has led to heightened scrutiny regarding the use of antibiotics in veterinary medicine. As a result, there is a growing focus on developing novel antibiotics that are effective against resistant strains while ensuring their responsible use. Regulatory bodies are also emphasizing the need for guidelines in antibiotic use, steering the market toward a more sustainable path. This segment is expected to witness steady growth as veterinarians continue to require effective treatments to combat bacterial infections, particularly in livestock where the economic impact can be substantial.

Antiparasitics:

The antiparasitic segment of the Veterinary API market is characterized by a wide range of products aimed at controlling parasitic infections in animals. This segment includes drugs targeting internal parasites like worms and external parasites like fleas and ticks. The increasing incidence of parasitic infections, influenced by factors such as climate change and global trade in animals, has created a robust demand for effective antiparasitic medications. Additionally, the growing awareness among pet owners regarding the importance of regular antiparasitic treatments plays a significant role in driving this market. Innovative formulations that enhance efficacy and reduce side effects are being developed, which further boosts market growth prospects.

Anti-inflammatory Drugs:

Anti-inflammatory drugs are essential for managing pain and inflammation in both livestock and companion animals. This segment is particularly important in veterinary medicine, as it helps enhance the quality of life for pets undergoing surgery or suffering from chronic pain conditions. The rise in pet ownership and the increased expenditure on veterinary care are major contributors to the growth of this segment. Moreover, ongoing research into new formulations and drug delivery systems is expected to drive innovation within this category, allowing for more effective treatments. With a growing understanding of pain management in veterinary medicine, the demand for anti-inflammatory drugs is anticipated to continue its upward trajectory in the coming years.

Antiviral Drugs:

The antiviral drugs segment in the Veterinary API market is crucial for managing viral infections in animals. While this segment is currently smaller compared to antibiotics and antiparasitics, it is gaining momentum due to the increasing incidence of viral infections in livestock and companion animals. Innovations in antiviral therapies are being driven by the need to address emerging viral diseases that can have significant health and economic impacts. Furthermore, as veterinary research progresses, the development of effective antiviral medications is likely to enhance the overall treatment options available to veterinarians, ensuring better health outcomes for animals and contributing to the market's growth.

Hormones:

Hormones in the Veterinary Active Pharmaceutical Ingredients market play a pivotal role in reproductive management and growth promotion in livestock. Hormonal treatments are critical for optimizing breeding practices and enhancing productivity in animal husbandry. The increasing global demand for meat and dairy products is driving the need for effective hormonal therapies to ensure optimal growth rates and reproductive efficiency. Additionally, the rising awareness among farmers regarding the benefits of hormonal treatments for livestock management is expected to facilitate market growth. Regulatory considerations regarding the use of hormones in animal production are also evolving, which may further shape the dynamics of this segment in the future.

By Application

Livestock:

The livestock application segment represents a significant portion of the Veterinary Active Pharmaceutical Ingredients market. With the global population continuously rising, the demand for meat, dairy, and other livestock products is at an all-time high. This, in turn, drives the need for effective veterinary APIs to maintain the health and productivity of livestock animals. The increasing focus on biosecurity measures and disease prevention strategies among farmers is also contributing to the growth of this segment. Additionally, the livestock sector is undergoing a transformation due to advancements in veterinary medicine, including novel APIs that enhance animal health and productivity, ensuring a robust market outlook.

Companion Animals:

The companion animals segment of the Veterinary API market is experiencing remarkable growth, primarily fueled by the rising trend of pet ownership globally. As more households consider pets as family members, there is an increasing willingness to invest in their health and well-being. This has resulted in a growing demand for veterinary pharmaceuticals, including vaccines, antiparasitics, and other active pharmaceutical ingredients. Moreover, pet owners are becoming increasingly aware of the importance of preventive health care, leading to a higher frequency of veterinary visits and, consequently, greater consumption of veterinary APIs. The segment is expected to continue expanding as more innovative treatments and products become available for dogs, cats, and other companion animals.

By Distribution Channel

Veterinary Hospitals:

Veterinary hospitals are a primary distribution channel for Veterinary Active Pharmaceutical Ingredients, providing a comprehensive range of services and medications for animal health. These facilities are equipped with skilled veterinarians who can diagnose and treat various ailments, thereby promoting the use of high-quality pharmaceuticals. The trend towards specialized veterinary care is driving the demand for APIs in these settings, as veterinarians utilize a combination of pharmaceuticals and therapeutic interventions to manage animal health. The continuous advancements in veterinary care, coupled with the increasing number of veterinary hospitals, are significant contributors to the growth of this distribution channel.

Veterinary Clinics:

Veterinary clinics serve as another vital distribution channel for Veterinary Active Pharmaceutical Ingredients. These clinics often cater to companion animals and offer a range of services from routine check-ups to emergency care. The rise in pet ownership and the growing awareness of pet health are encouraging more pet owners to seek veterinary services. Furthermore, veterinary clinics are increasingly stocking a variety of APIs to cater to diverse health needs, including preventive care, chronic disease management, and acute illness treatment. This segment is expected to witness steady growth as pet owners prioritize regular veterinary visits and effective treatments for their animals.

Pharmacies & Drug Stores:

Pharmacies and drug stores play a crucial role in the distribution of Veterinary Active Pharmaceutical Ingredients, particularly for over-the-counter medications and supplements for animals. The increasing accessibility of veterinary medicines through retail channels is enhancing consumer convenience, allowing pet owners to purchase necessary medications without an immediate visit to a veterinarian. This trend is particularly evident in regions with a significant pet ownership base. As more pet owners seek easy access to veterinary APIs for routine care and preventive measures, pharmacies and drug stores are expected to see a growing share of the market. The ongoing expansion of pet product lines in these retail environments is likely to support this growth further.

Online Pharmacies:

The emergence of online pharmacies has transformed how Veterinary Active Pharmaceutical Ingredients are distributed. The convenience of purchasing medications online has become increasingly appealing to pet owners, particularly in light of the COVID-19 pandemic, which accelerated the shift towards digital platforms. Online pharmacies provide a vast selection of veterinary APIs and often offer competitive pricing and home delivery services, making it easier for pet owners to manage their pets' health. This distribution channel is expected to experience significant growth as more consumers embrace e-commerce solutions for purchasing veterinary products. The ongoing advancements in technology and logistics for online retail are likely to further enhance this segment's appeal.

By Ingredient Type

Tetracyclines:

Tetracyclines are one of the most widely used classes of antibiotics in the Veterinary Active Pharmaceutical Ingredients market. These drugs are effective against a broad spectrum of bacterial infections in animals, making them a staple in veterinary medicine. The increasing incidence of bacterial infections in both livestock and companion animals is driving the demand for tetracyclines. Furthermore, the development of new formulations and delivery methods is expected to enhance the therapeutic efficacy of these antibiotics. However, the growing concern over antibiotic resistance may influence the regulatory landscape and necessitate the development of alternative solutions or guidelines for responsible use in veterinary medicine.

Macrolides:

Macrolides are another essential class of antibiotics used in veterinary medicine, primarily for treating respiratory infections and other bacterial diseases. They are favored for their broad-spectrum activity and favorable safety profile in various animal species. The increasing focus on animal welfare and health management is driving the demand for macrolides, particularly in livestock where respiratory diseases can lead to significant economic losses. Research and development efforts aimed at improving the efficacy and reducing the side effects of macrolides are expected to support market growth, ensuring veterinarians have access to effective treatment options for their patients.

Penicillins:

Penicillins have long been a cornerstone in veterinary medicine due to their effectiveness against various bacterial infections. Their relative affordability and established safety profile have made them a popular choice among veterinarians for treating a wide range of ailments in both livestock and companion animals. As the demand for veterinary pharmaceuticals continues to grow, the penicillin segment is expected to maintain its relevance. However, the increasing concern over antibiotic resistance necessitates ongoing research into alternative therapies and the responsible use of penicillins, which may shape future dynamics within this segment.

Sulfonamides:

Sulfonamides are a class of antimicrobial agents widely used in veterinary medicine for treating infections caused by susceptible bacteria. Known for their broad-spectrum activity, sulfonamides are particularly effective against a variety of infections in both companion animals and livestock. The growing awareness of animal health and the increasing prevalence of infectious diseases are driving demand for sulfonamides. As veterinarians seek effective treatments, research into new formulations and combinations with other drugs is expected to enhance the therapeutic potential of sulfonamides, contributing to their continued relevance in the veterinary API market.

Aminoglycosides:

Aminoglycosides are used in veterinary medicine primarily for their effectiveness against gram-negative bacterial infections. This class of antibiotics is particularly important for treating severe infections in animals, especially in settings where other antibiotics may not be effective. The increasing occurrence of resistant bacterial strains has led to a renewed emphasis on the responsible use of aminoglycosides, ensuring their effectiveness in treating infections. As the veterinary community continues to prioritize effective infection control measures, the demand for aminoglycosides is expected to persist, with ongoing research aimed at developing novel formulations and treatment regimens.

By Region

The North American Veterinary Active Pharmaceutical Ingredients market stands out as a significant player in the global landscape, attributed primarily to the advanced veterinary healthcare infrastructure and high investments in research and development. The region is expected to account for over 35% of the global market share by 2035, driven by a strong emphasis on companion animal health and a well-established network of veterinary hospitals and clinics. Additionally, the growing awareness among pet owners regarding preventive healthcare measures continues to bolster demand for veterinary APIs in North America. The market is projected to grow at a CAGR of approximately 7% during the forecast period, reflecting ongoing advancements in veterinary medicine and consumer preferences.

Europe is another key region in the Veterinary Active Pharmaceutical Ingredients market, holding a substantial share due to its robust agricultural sector and high standards of animal welfare. The European market is characterized by strict regulatory frameworks and guidelines governing the use of veterinary pharmaceuticals, which enhance the quality and safety of veterinary APIs. The region is anticipated to witness steady growth as the demand for innovative treatments, particularly for livestock, continues to rise. Additionally, increasing consumer awareness regarding the welfare of companion animals is expected to further elevate the demand for veterinary APIs. By 2035, it is projected that Europe's market share will be around 30%, reflecting its significance in the global veterinary API landscape.

Opportunities

One of the most significant opportunities in the Veterinary Active Pharmaceutical Ingredients market lies in the growing trend of pet humanization. As pet owners increasingly view their pets as family members, there is a corresponding rise in the demand for high-quality veterinary care and pharmaceuticals. This trend encourages investment in innovative veterinary APIs that cater to the specific health needs of companion animals, ranging from preventive care to treatment of chronic conditions. Moreover, the increasing awareness regarding the importance of regular veterinary check-ups creates a larger market for pharmaceuticals, as veterinarians can recommend appropriate active ingredients tailored to individual animal health needs. This presents an opportunity for manufacturers to develop targeted therapies and market new APIs effectively.

Another opportunity exists in the realm of veterinary telemedicine and online veterinary services. The COVID-19 pandemic has accelerated the adoption of telemedicine in veterinary practice, allowing pet owners greater access to veterinary care and consultations. This development has facilitated the growth of online pharmacies, enabling pet owners to purchase veterinary active pharmaceutical ingredients conveniently. As more veterinarians establish online presence and services, the demand for veterinary APIs through digital platforms is expected to rise. Furthermore, this opens avenues for collaboration between pharmaceutical companies and digital health platforms to create comprehensive solutions that integrate telemedicine with the provision of veterinary medications, enhancing customer experience and adherence to treatment.

Threats

Despite the growth potential, the Veterinary Active Pharmaceutical Ingredients market faces certain threats that could impact its trajectory. One of the primary threats is the increasing concern over antibiotic resistance, which poses significant challenges for veterinary medicine. The rising prevalence of resistant strains among pathogens can limit treatment options for veterinarians, leading to potential public health risks and economic implications within the livestock sector. Regulatory agencies are also tightening guidelines regarding the use of antibiotics in veterinary medicine, necessitating the development of alternative therapies and reducing the usage of certain antibiotics. This evolving landscape demands ongoing research and innovation in the development of new active ingredients that can effectively address infectious diseases while minimizing resistance.

Another significant concern for the Veterinary Active Pharmaceutical Ingredients market is the potential impact of economic fluctuations and trade policies. Economic downturns can lead to reduced consumer spending on pet care and veterinary services, affecting the demand for veterinary pharmaceuticals. Additionally, trade regulations and tariffs can complicate the supply chain for veterinary APIs, particularly for companies that rely on international sourcing or distribution of raw materials. These external factors could hinder market growth and necessitate strategic adjustments in operations for companies operating within this sector, potentially impacting their overall competitiveness and profitability.

Competitor Outlook

• Zoetis Inc.
• Merck Animal Health
• Elanco Animal Health
• Boehringer Ingelheim
• Virbac
• Dechra Pharmaceuticals
• Ceva Santé Animale
• Vetoquinol S.A.
• Phibro Animal Health Corporation
• Huvepharma
• Intas Pharmaceuticals
• Neogen Corporation
• PetMed Express
• Merial (part of Boehringer Ingelheim)
• Med-Pharmex, Inc.

The competitive landscape of the Veterinary Active Pharmaceutical Ingredients market is characterized by a mix of established global players and emerging companies. Major companies, such as Zoetis Inc., Merck Animal Health, and Elanco Animal Health, dominate the market with a wide range of products and extensive distribution networks. These companies invest heavily in research and development to innovate and expand their product offerings, ensuring they stay ahead in the competitive arena. Additionally, partnerships and collaborations with veterinary practices and online pharmacies are becoming increasingly common, as companies seek to enhance their market reach and provide comprehensive solutions to veterinarians and pet owners alike.

Furthermore, companies like Boehringer Ingelheim and Virbac focus on leveraging their expertise in animal health to introduce specialized veterinary APIs, addressing specific health challenges faced by livestock and companion animals. Their commitment to quality and innovation allows these companies to build strong brand loyalty among veterinarians. Additionally, the entry of new players, particularly from emerging markets, introduces fresh competition, creating opportunities for advancements in product development and pricing strategies. The overall competitive landscape is dynamic, with companies continually adapting to market demands while striving to maintain their competitive edge.

As the market evolves, it is essential for companies to keep pace with regulatory changes and shifting consumer preferences. Manufacturers are increasingly focusing on sustainable practices and the development of eco-friendly veterinary APIs, aligning their strategies with growing trends in environmental responsibility. In addition, companies like Neogen Corporation and Intas Pharmaceuticals are expanding their portfolios to include innovative technologies and solutions that cater to the evolving needs of veterinarians and animal owners. The continuous advancements in veterinary medicine, coupled with the rising demand for high-quality active pharmaceutical ingredients, will shape the competitive landscape, ensuring that only those companies that prioritize innovation and adaptability will thrive.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Virbac
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Huvepharma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Zoetis Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 PetMed Express
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Vetoquinol S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Med-Pharmex, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Neogen Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck Animal Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Elanco Animal Health
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Intas Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Dechra Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ceva Santé Animale
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Phibro Animal Health Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Merial (part of Boehringer Ingelheim)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Application
    • 6.1.1 Livestock
    • 6.1.2 Companion Animals
  • 6.2 Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Product Type
    • 6.2.1 Antibiotics
    • 6.2.2 Antiparasitics
    • 6.2.3 Anti-inflammatory Drugs
    • 6.2.4 Antiviral Drugs
    • 6.2.5 Hormones
  • 6.3 Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Ingredient Type
    • 6.3.1 Tetracyclines
    • 6.3.2 Macrolides
    • 6.3.3 Penicillins
    • 6.3.4 Sulfonamides
    • 6.3.5 Aminoglycosides
  • 6.4 Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Distribution Channel
    • 6.4.1 Veterinary Hospitals
    • 6.4.2 Veterinary Clinics
    • 6.4.3 Pharmacies & Drug Stores
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Veterinary Active Pharmaceutical Ingredients Manufacturing Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Veterinary Active Pharmaceutical Ingredients Manufacturing market is categorized based on

By Product Type

• Antibiotics
• Antiparasitics
• Anti-inflammatory Drugs
• Antiviral Drugs
• Hormones

By Application

• Livestock
• Companion Animals

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies & Drug Stores
• Online Pharmacies

By Ingredient Type

• Tetracyclines
• Macrolides
• Penicillins
• Sulfonamides
• Aminoglycosides

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis Inc.
• Merck Animal Health
• Elanco Animal Health
• Boehringer Ingelheim
• Virbac
• Dechra Pharmaceuticals
• Ceva Santé Animale
• Vetoquinol S.A.
• Phibro Animal Health Corporation
• Huvepharma
• Intas Pharmaceuticals
• Neogen Corporation
• PetMed Express
• Merial (part of Boehringer Ingelheim)
• Med-Pharmex, Inc.